Publication: Nevirapine concentrations during the first month of life and maternal efavirenz washout in high-risk hiv-exposed infants receiving triple antiretroviral prophylaxis
Issued Date
2019-02-01
Resource Type
ISSN
15320987
08913668
08913668
Other identifier(s)
2-s2.0-85059909055
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Infectious Disease Journal. Vol.38, No.2 (2019), 152-156
Suggested Citation
Suvaporn Anugulruengkitt, Tim R. Cressey, Piyarat Suntarattiwong, Pradthana Ounchanum, Ussanee Srirompotong, Watsamon Jantarabenjakul, Jiratchaya Sophonphan, Yardpiroon Tawon, Sunti Punnahitanon, Chitsanu Pancharoen, Kulkanya Chokephaibulkit, Thanyawee Puthanakit Nevirapine concentrations during the first month of life and maternal efavirenz washout in high-risk hiv-exposed infants receiving triple antiretroviral prophylaxis. Pediatric Infectious Disease Journal. Vol.38, No.2 (2019), 152-156. doi:10.1097/INF.0000000000002195 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51930
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Nevirapine concentrations during the first month of life and maternal efavirenz washout in high-risk hiv-exposed infants receiving triple antiretroviral prophylaxis
Other Contributor(s)
Harvard T.H. Chan School of Public Health
Chulalongkorn University
University of Liverpool
The HIV Netherlands Australia Thailand Research Collaboration
Faculty of Medicine, Thammasat University
Khon Kaen Regional Hospital
Faculty of Medicine, Siriraj Hospital, Mahidol University
Queen Sirikit National Institute of Child Health
Faculty of Asociated Medical Sciences (PHPT/IRD)
Chiangrai Prachanukroh Hospital
Chulalongkorn University
University of Liverpool
The HIV Netherlands Australia Thailand Research Collaboration
Faculty of Medicine, Thammasat University
Khon Kaen Regional Hospital
Faculty of Medicine, Siriraj Hospital, Mahidol University
Queen Sirikit National Institute of Child Health
Faculty of Asociated Medical Sciences (PHPT/IRD)
Chiangrai Prachanukroh Hospital
Abstract
© 2018 Wolters Kluwer Health, Inc. All rights reserved. Background: Triple-drug infant antiretroviral prophylaxis containing nevirapine (NVP) is increasingly used to prevent HIV transmission among neonates at high risk of HIV infection. Our aim was to describe NVP concentration from birth through the first month of life. Methods: High-risk HIV-exposed neonates were enrolled in a prospective cohort in Thailand. High-risk neonates defined as maternal HIV RNA >50 copies/mL before delivery or mother received antiretroviral treatment for <12 weeks before delivery. Neonates received zidovudine (4 mg/kg) and lamivudine (2 mg/kg) twice daily, plus NVP (4 mg/kg) once daily (no lead-in) from birth to 6 weeks of life. Infant plasma samples were collected at 1, 2, 14 or 2, 7, 28 days of life. NVP trough concentrations (C24) were estimated using a population pharmacokinetic model and target C24 was ≥0.1 mg/L. "Washout" efavirenz (EFV) concentrations were assessed in infants whose mother received EFV-based antiretroviral treatment. Results: A total of 48 infants were included: 25 (52%) were male and 12 (25%) were preterm (gestational age 34-37 weeks). Median (interquartile range) predicted NVP C24 were 1.34 mg/L (1.13-1.84), 2.24 (2.00-2.59), 2.78 (2.61-3.12), 2.20 (1.86-2.44) and 0.81 (0.58-0.98) on days 1, 2, 7, 14 and 28 of life, respectively. NVP C24 was not significantly different between term and preterm infants. All infants maintained NVP C24 ≥0.1 mg/L. EFV via placental transfer remained detectable in infants up to 7 days of life. Conclusions: NVP 4 mg/kg daily from birth provided adequate prophylactic concentrations during the first month of life in high-risk HIV-exposed neonates.